 |
|
|
|
 |
|
|
| Article 1 to 8 out of 8 concerning Lab21 Limited
|
-
Predictive genetic test for bowel cancer treatment is introduced in the UK
(03/20/2008)
Amgen and Lab21 in Partnership Agreement for New Cancer Therapy Test
Amgen Limited UK and Lab21 have announced their partnership to introduce a new genetic therapy test for advanced bowel cancer treatment in the UK. Under the terms of the agreement, Lab21 will provide a screening test to indicate which patients are ...
-
Lab21 signs a license with Celera for one of the first diagnostic tests for cirrhosis risk in hepatitis C patients
(02/25/2008)
Lab21 announced that it has obtained a licence from Celera, an Applera Corporation business, to provide access to its test for cirrhosis risk in patients with chronic hepatitis C viral (HCV) infection in the UK and Ireland.The test, known as CRS7, ...
-
Lab21 launches cancer gene testing service
(01/28/2008)
Lab21 announced the launch of a cancer gene testing service from its Cambridge laboratories. Lab21 is providing a test for analysis of the K-ras gene. K-ras plays an important role in cell growth regulation and the proliferation of cancer cells. In ...
-
Lab21 appoints new CEO
(11/07/2007)
Lab21 has announced the appointment of Graham Mullis as its new CEO. Graham has held executive positions at FTSE and Nasdaq listed medical device companies including 1-800 Contacts Inc and Biocompatibles International PLC and pharmaceutical roles at ...
-
Lab21 Announces Licence Agreement with Ark Therapeutics for Predictive Coronary Heart Disease Diagnostic
(10/15/2007)
Lab 21 announced that it has entered into an exclusive license with Ark Therapeutics of a diagnostic test to measure autoantibodies to oxidized low density lipoprotein (oxLDL), which is a predictive risk factor for the development of coronary heart ...
-
New syphilis test provides quicker and easier diagnosis
(08/16/2007)
Newmarket Laboratories, part of the Lab21 Group has developed a new diagnostic test for syphilis which is rapid, accurate and easy to use, according to the company. The new syphilis IgM antibody test uses recombinant antigens, which have a high ...
-
Lab21 secures additional IP for Hepatitis C diagnostics
(10/21/2005)
Lab 21 announced that it has completed an agreement to exclusively license the Hepatitis C (HCV) diagnostic technology and associated patent applications of Dr. Carol Holland (TROY, MI, USA). The deal was brokered by UTEK-EKMS (CAMBRIDGE, MA, USA), ...
-
Lab21 - a new kind of company
(07/18/2005)
Antiviral drug discovery services and clinical trials support
A new company - Lab21 - has been launched to provide technically advanced drug discovery and clinical trials services to the pharmaceutical and biotech industries. Testing is performed in state-of-the-art laboratories in Cambridge (UK), with ...
Additional information
Lab21 Limited
Fareham, United Kingdom
Company
|
|
|
|
|
|
Top
